

**The Twenty-Second
Irving L. Schwartz Lectureship**
In
STRUCTURAL & CHEMICAL BIOLOGY

Craig M. Crews, PhD

John C. Malone Professor of Molecular,
Cellular, and Developmental Biology (MCDB),
Departments of MCDB, Chemistry,
and Pharmacology,
Yale University

“PROTACs and Targeted Protein
Degradation:
A New Therapeutic Modality”

Thursday, October 27, 2022
2:15 pm

Hatch Auditorium
Icahn School of Medicine at Mount Sinai
1468 Madison Avenue, 2nd Floor
New York, NY 10029

Reception to follow the lecture



Department of Pharmacological Sciences

Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
1425 Madison Avenue
New York, New York 10029
Tel. 212-659-8647

**The
Twenty-Second
Irving L. Schwartz
Lectureship**
in Structural
and Chemical
Biology





Irving L. Schwartz, MD
(1918 – 2011)

Dr. Schwartz was the first Dean of the Mount Sinai Graduate School of Biological Sciences from 1965 to 1980 when he became Dean Emeritus.

He was also the founding chairman of the Department of Physiology and Biophysics (currently the Department of Pharmacological Sciences) and the Lamport Distinguished Professor until his retirement in 1989.

Under Dr. Schwartz's early leadership, Mount Sinai grew as a center of excellence in translational research. He believed in the "vital interdisciplinary interactions among clinicians, basic scientists, medical students, and graduate students within one institution." Dr. Schwartz's interests in biomedical research and education were far reaching, addressing fundamental problems of body fluid regulation, secretory phenomena and neurophysiology. His work, originally in whole animal and organ physiology, evolved over the years to the cellular level, and ultimately to the molecular level. He had a major interest in the function of neurohypophyseal and other peptides. His studies on peptides ranged from bedside observations, to biochemical mechanisms of action, to the definition of three-dimensional structure of such molecules in solution as well as in the crystalline state. The work of his group on the molecular conformation of hormones in solution pioneered structure-function analysis based on the tertiary structure of molecules.



Craig M. Crews, PhD

Dr. Crews is the John C. Malone Professor of Molecular, Cellular, and Developmental Biology (MCDB), and Professor of Chemistry and Pharmacology at Yale University. He received his

BA degree in Chemistry from the University of Virginia and his PhD degree in Biochemistry from Harvard University.

On the faculty at Yale since 1995, his laboratory has developed the use of small molecules to control intracellular protein levels. In 2003, he co-founded Proteolix, Inc., whose proteasome inhibitor, Kyprolis™ received FDA approval for the treatment of multiple myeloma. Dr. Crews' lab is also credited with founding the field of 'Targeted Protein Degradation' drug development technology, i.e., PROTACs, which has the potential to target currently 'undruggable' disease causing proteins.

In 2013, Dr. Crews launched the New Haven-based biotech venture, Arvinas, Inc., which is testing the first PROTAC-based drugs in clinical trials for prostate and breast cancer. Since then he has founded two additional biopharmas, Halda Therapeutics and Siduma Therapeutics.

Dr. Crews has received numerous awards and honors, including the Ehrlich Award for Medicinal Chemistry (2014), a NIH R35 Outstanding Investigator Award (2015), the AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2017), the Khorana Prize from the Royal Society of Chemistry (2018), the Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019), the Heinrich Wieland Prize (2020), the Scheele Prize (2021), and the Connecticut Medal of Technology (2022).

In Honor of

IRVING L. SCHWARTZ

Scientist, scholar, teacher, physician

1993	Albert J. Hudspeth, MD, PhD <i>University of Texas-Southwestern Medical Center</i>
1995	Charles F. Stevens, MD, PhD <i>The Salk Institute for Biological Studies</i>
1998	Wayne L. Hubbell, MD, PhD <i>University of California at Los Angeles</i>
2000	Richard N. Bergman, PhD <i>University of Southern California</i>
2005	Stephen C. Harrison, PhD <i>Harvard Medical School</i>
2006	Roger D. Kornberg, PhD* <i>Stanford University</i>
2007	Kurt Wüthrich, PhD* <i>The ETH Zürich, Switzerland</i>
2008	Stuart L. Schreiber, PhD <i>Harvard University, The Broad Institute, HHMI</i>
2009	Michael G. Rosenfeld, MD <i>University of California, San Diego, HHMI</i>
2010	Klaus Schulten, PhD <i>University of Illinois Urbana-Champaign</i>
2011	Kevan Shokat, PhD <i>University of California, San Francisco, HHMI</i>
2012	Tony Hunter, PhD <i>The Salk Institute for Biological Studies</i>
2013	David E. Shaw, PhD <i>D. E. Shaw Research, Columbia University</i>
2014	Joachim Frank, PhD* <i>Columbia University, HHMI</i>
2015	Wayne A. Hendrickson, PhD <i>Columbia University</i>
2016	Jennifer Doudna, PhD* <i>University of California, Berkeley, HHMI</i>
2017	Stephen W. Fesik, PhD <i>Vanderbilt University School of Medicine</i>
2018	Thomas R. Cech, PhD* <i>University of Colorado Boulder, HHMI</i>
2019	David Baker, PhD <i>University of Washington, HHMI</i>
2020	Joan A. Steitz, PhD <i>Yale University, HHMI</i>
2021	Karolin Luger, PhD <i>University of Colorado, HHMI</i>

* The Nobel Prize Winner